Literature DB >> 9665303

Provisional quality control parameters and interpretive criteria for testing susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to quinupristin/dalfopristin (RP59500). Antimicrobial Testing Quality Control Group.

P Fuchs1, A Barry, S Brown.   

Abstract

Studies were undertaken to select tentative criteria for susceptibility testing of quinupristin/dalfopristin against Streptococcus pneumoniae and Haemophilus influenzae. Against 612 isolates of Streptococcus pneumoniae, MICs of quinupristin/dalfopristin were < or = 1.0 microg/ml for all but one strain. With a tentative MIC breakpoint of either < or = 1.0 microg/ml or < or = 2.0 microg/ml for susceptible, a disk diffusion zone diameter breakpoint of > or = 19 mm embraced all but two of the susceptible pneumococci; > or = 16 mm included all strains. For Haemophilus influenzae, MICs of quinupristin/dalfopristin clustered near the tentative breakpoints; 91.5% of the MICs were 2.0 to 8.0 microg/ml. This precluded satisfactory performance of the disk diffusion test in discriminating between resistant and susceptible isolates unless MIC breakpoints are modified for this species: clinical experience will be needed before that can be justified. Based on data from a multilaboratory study, the following quality control limits are proposed for Streptococcus pneumoniae ATCC 49619 when testing quinupristin/dalfopristin: 0.25 to 1.0 microg/ml for broth microdilution tests and 19 to 24 mm for disk diffusion tests. For tests of Haemophilus influenzae ATCC 29247, MIC limits are 2.0 to 16 microg/ml; disk tests were very reproducible but are not yet recommended.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665303     DOI: 10.1007/bf01691118

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

1.  Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

2.  RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci.

Authors:  G L Archer; P Auger; G V Doern; M J Ferraro; P C Fuchs; J H Jorgensen; D E Low; P R Murray; L B Reller; C W Stratton
Journal:  Diagn Microbiol Infect Dis       Date:  1993 Mar-Apr       Impact factor: 2.803

Review 3.  Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience.

Authors:  D E Low
Journal:  Microb Drug Resist       Date:  1995       Impact factor: 3.431

4.  In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci.

Authors:  C C Johnson; L Slavoski; M Schwartz; P May; P G Pitsakis; A L Shur; M E Levison
Journal:  Diagn Microbiol Infect Dis       Date:  1995-03       Impact factor: 2.803

5.  In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

6.  In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

7.  The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination.

Authors:  H C Neu; N X Chin; J W Gu
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

8.  In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500.

Authors:  D H Bouanchaud
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

  8 in total
  2 in total

Review 1.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species.

Authors:  Glenn A Pankuch; Linda M Kelly; Gengrong Lin; Andre Bryskier; Catherine Couturier; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.